We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Boston Biomedica Sells Diagnostics and Biotech Divisions

By Labmedica staff writers
Posted on 27 Sep 2004
The sale of substantially all of the assets and selected liabilities of the BBI Diagnostics and BBI Biotech divisions of Boston Biomedica (West Bridgewater, MA, USA) have been sold to SeraCare Life Sciences, Inc. More...
(Oceanside, CA, USA) for U.S.$30 million in cash, plus the assumption of certain liabilities. Boston Biomedica has changed its name to Pressure BioSciences, Inc. (PBI).

¡°This transaction also enables Pressure BioSciences to focus our efforts on our novel pressure cycling activities (PCT),¡± commented Richard T. Schumacher, president and CEO of Pressure BioSciences. ¡°To this end, we continue to plan for the commercial release of our new bench top PCT instrument by the end of the year, to collaborate with leading researchers and laboratories throughout North America in their use of PCT to generate important data in the areas of genomics and proteomics, and to expand our already strong PCT intellectual property portfolio.¡±

PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels to control biomolecular interactions. Applications range from genomic and proteomic sample preparation, pathogen inactivation, control of enzymes, and protein purification. PBI holds 13 U.S. and foreign patents covering multiple applications of PCT in the life sciences field.



Related Links:
Pressure BioSciences
SeraCare

New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
New
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.